非小细胞肺癌液体活检技术研究进展
|
摘要
随着精准医学和个体化治疗在肿瘤领域的发展,采用肿瘤分子生物学特性进行监测的要求越来越高,液体活检技术以其独有的无创性、便捷性、高重复性等特点在临床上得到了广泛关注,在未来有着巨大的发展潜力。非小细胞肺癌(NSCLC)占肺癌病人85%～90%,针对NSCLC,该文以液体活检循环肿瘤细胞、循环肿瘤DNA和外泌体,对NSCLC病人的临床应用做如下综述。
With the development of precision medicine and individualized treatment in the field of cancer therapy,the demand of monitoring tumor molecular biology characteristics is elevated. Liquid biopsy technology has attracted extensive attention in clinical practice due to its unique features of noninvasive,convenient and high repeatability and has the huge development potential in the future. Nonsmall cell lung cancer( NSCLC) accounts from 85% to 90% in patients with lung cancer. The clinical application of liquid biopsy of circulating tumor cells,circulating tumor DNA and exosomes in patients with NSCLC were reviewed as follows.
With the development of precision medicine and individualized treatment in the field of cancer therapy,the demand of monitoring tumor molecular biology characteristics is elevated. Liquid biopsy technology has attracted extensive attention in clinical practice due to its unique features of noninvasive,convenient and high repeatability and has the huge development potential in the future. Nonsmall cell lung cancer( NSCLC) accounts from 85% to 90% in patients with lung cancer. The clinical application of liquid biopsy of circulating tumor cells,circulating tumor DNA and exosomes in patients with NSCLC were reviewed as follows.
引文
[1] FERLAY J,SHIN HR,BRAY F,et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917.
[2] CHEN WQ,ZHANG SW,ZENG HM,et al. Report of cancer incidence and mortality in China,2010[J]. China Cancer,2014,23(1):1-10.
[3] EDWARDS BK,NOONE AM,MARIOTTO AB,et al. Annual report to the nation on the status of cancer,1975—2010,featuring prevalence of comorbidity and impact on survival among persons with lung,colorectal,breast,or prostate cancer[J]. Cancer,2014,120(9):1290-1314.
[4] NAKATANI K,ISHIKAWA T. Breakthrough technologies 2015,MIT technologies review[J]. Nature,2015,120(9):69-72.
[5] ROLFO C,CASTIGLIA M,HONG D,et al. Liquid biopsies in lung cancer:the new ambrosia of researchers[J]. Biochim Biophys Acta,2014,1846(2):539-546.
[6] CABEL L,PROUDHON C,GORTAIS H,et al. Circulating tumor cells:clinical validity and utility[J]. Int J Clin Oncol,2017,120(9):1105-1112.
[7] RACK B,SCHINDLBECK C,JUCKSTOCK J,et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients[J]. J Natl Cancer Inst,2014,106(5):dju066.
[8] DORSEY JF,KAO GD,MACARTHUR KM,et al. Tracking viable circulating tumor cells(CTCs)in the peripheral blood of nonsmall cell lung cancer(NSCLC)patients undergoing definitive radiation therapy:pilot study results[J]. J Clin Oncol,2011,29(12):1556-1563.
[9] ILIE M,HOFMAN V,LONG-MIRA E,et al.”Sentinel”circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLo S One,2014,9(10):e111597. DOI:10. 1371/journal. pone. 0111597.
[10] FIORELLI A,ACCARDO M,CARELLI E,et al. Circulating tumor cells in diagnosing lung cancer:clinical and morphologic analysis[J]. Ann Thorac Surg,2015,99:1899-1905.
[11] KREBS MG,SLOANE R,PRIEST L,et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmall-cell lung cancer[J]. J Clin Oncol,2011,29(12):1556-1563.
[12] NICOLAZZO C,RAIMONDI C,MANCINI M,et al. 2016. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab[J]. Sci Rep,2016,6:31726.
[13] YU M,BARDIA A,WITTNER BS,et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition[J]. Science,2013,339:580-584.
[14] JAHR S,HENTZE H,ENGLISCH S,et al. DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res,2001,61(4):1659-1665.
[15] QIU M,WANG J,XU Y,et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer:a meta-analysis[J]. Cancer Epidemiol Biomarkers Prev,2015,24(1):206-212.
[16] NIE K,JIA Y,ZHANG X,et al. Cell-free circulating tumor DNA in plasma/serum of non-small cellluncancer[J]. Nat Med,2014,20(4):430-435.
[17] MARCHETTI A,DEL GRAMMASTRO M,FELICIONI L,et al.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a real-time liquid biopsy for treatment[J]. PLo S One,2014,9(8):e103883. DOI:10. 1371/journal. pone. 0103883.
[18] CHEN KZ,LOU F,YANG F,et al. Circulating Tumor DNA Detection in Early Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing[J]. Sci Rep,2016,6:31985.
[19] ROSELL R,KARACHALIOU N. Lung cancer:Using ct DNA to track EGFR and KRAS mutations in advanced-stage disease[J].Nat Rev ClinOncol,2016,13(7):401-402.
[20] LOTVALL J,VALADI H. Cell to cell signaling via exosomes through esRNA[J]. Cell Adh Migr,2009,1(3):156-158.
[21] TAVERNA S,GIALLOMBARDO M,GIL-BAZO I,et al. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patient critical analysis of evidence and potentional role in clinical practice[J]. Oncotarget,2016,7(19):28748-28760.
[22] MATHIVANAN S,FAHNER CJ,REID GE,et al. ExoCarta 2012:database of exosomal proteins,RNA and lipids[J]. Nucleic Acids Res,2012,40(1):1241-1244.
[23] ZERINGER E,BARTA T,LI M,et al. Strategies for isolation of exosomes[J]. Cold Spring Harb Protoc,2015,2015(4):319-323.
[24] ALOS L,MOYANO S,NADAL A,et al. Human papillomaviruses are identified in a subgroup of ainonasal squamous cell carcinomas with favorable outcome[J]. Cancer,2009,115(12):2701-2709.
[25] AL-NEDAWI K,MEEHAN B,KERBEL RS,et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR[J]. Proc Natl Acad Sci USA,2009,106(10):3794-3799.
[26] WANG Y,YI J,CHEN X,et al. The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-βand IL-10[J]. Oncology Letters,2016,11(2):1527-1530.
[27] RAHMAN MA,BARGER JF,LOVAT F,et al. Lung cancer exosomes as drivers of epithelial mesenchymal transition[J]. Oncotarget,2016,7(34):54852-54866.
[28] TAYLOR DD,GERCEL-TAYLOR C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer[J]. Gynecol Oncol,2008,110(1):13-21.
[29] SUN T,KALIONIS B,LV G,et al. Role of Exosomal Noncoding RNAs in Lung Carcinogenesis[J]. Biomed Res Int,2015,2015:125807.
[2] CHEN WQ,ZHANG SW,ZENG HM,et al. Report of cancer incidence and mortality in China,2010[J]. China Cancer,2014,23(1):1-10.
[3] EDWARDS BK,NOONE AM,MARIOTTO AB,et al. Annual report to the nation on the status of cancer,1975—2010,featuring prevalence of comorbidity and impact on survival among persons with lung,colorectal,breast,or prostate cancer[J]. Cancer,2014,120(9):1290-1314.
[4] NAKATANI K,ISHIKAWA T. Breakthrough technologies 2015,MIT technologies review[J]. Nature,2015,120(9):69-72.
[5] ROLFO C,CASTIGLIA M,HONG D,et al. Liquid biopsies in lung cancer:the new ambrosia of researchers[J]. Biochim Biophys Acta,2014,1846(2):539-546.
[6] CABEL L,PROUDHON C,GORTAIS H,et al. Circulating tumor cells:clinical validity and utility[J]. Int J Clin Oncol,2017,120(9):1105-1112.
[7] RACK B,SCHINDLBECK C,JUCKSTOCK J,et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients[J]. J Natl Cancer Inst,2014,106(5):dju066.
[8] DORSEY JF,KAO GD,MACARTHUR KM,et al. Tracking viable circulating tumor cells(CTCs)in the peripheral blood of nonsmall cell lung cancer(NSCLC)patients undergoing definitive radiation therapy:pilot study results[J]. J Clin Oncol,2011,29(12):1556-1563.
[9] ILIE M,HOFMAN V,LONG-MIRA E,et al.”Sentinel”circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLo S One,2014,9(10):e111597. DOI:10. 1371/journal. pone. 0111597.
[10] FIORELLI A,ACCARDO M,CARELLI E,et al. Circulating tumor cells in diagnosing lung cancer:clinical and morphologic analysis[J]. Ann Thorac Surg,2015,99:1899-1905.
[11] KREBS MG,SLOANE R,PRIEST L,et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmall-cell lung cancer[J]. J Clin Oncol,2011,29(12):1556-1563.
[12] NICOLAZZO C,RAIMONDI C,MANCINI M,et al. 2016. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab[J]. Sci Rep,2016,6:31726.
[13] YU M,BARDIA A,WITTNER BS,et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition[J]. Science,2013,339:580-584.
[14] JAHR S,HENTZE H,ENGLISCH S,et al. DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res,2001,61(4):1659-1665.
[15] QIU M,WANG J,XU Y,et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer:a meta-analysis[J]. Cancer Epidemiol Biomarkers Prev,2015,24(1):206-212.
[16] NIE K,JIA Y,ZHANG X,et al. Cell-free circulating tumor DNA in plasma/serum of non-small cellluncancer[J]. Nat Med,2014,20(4):430-435.
[17] MARCHETTI A,DEL GRAMMASTRO M,FELICIONI L,et al.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a real-time liquid biopsy for treatment[J]. PLo S One,2014,9(8):e103883. DOI:10. 1371/journal. pone. 0103883.
[18] CHEN KZ,LOU F,YANG F,et al. Circulating Tumor DNA Detection in Early Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing[J]. Sci Rep,2016,6:31985.
[19] ROSELL R,KARACHALIOU N. Lung cancer:Using ct DNA to track EGFR and KRAS mutations in advanced-stage disease[J].Nat Rev ClinOncol,2016,13(7):401-402.
[20] LOTVALL J,VALADI H. Cell to cell signaling via exosomes through esRNA[J]. Cell Adh Migr,2009,1(3):156-158.
[21] TAVERNA S,GIALLOMBARDO M,GIL-BAZO I,et al. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patient critical analysis of evidence and potentional role in clinical practice[J]. Oncotarget,2016,7(19):28748-28760.
[22] MATHIVANAN S,FAHNER CJ,REID GE,et al. ExoCarta 2012:database of exosomal proteins,RNA and lipids[J]. Nucleic Acids Res,2012,40(1):1241-1244.
[23] ZERINGER E,BARTA T,LI M,et al. Strategies for isolation of exosomes[J]. Cold Spring Harb Protoc,2015,2015(4):319-323.
[24] ALOS L,MOYANO S,NADAL A,et al. Human papillomaviruses are identified in a subgroup of ainonasal squamous cell carcinomas with favorable outcome[J]. Cancer,2009,115(12):2701-2709.
[25] AL-NEDAWI K,MEEHAN B,KERBEL RS,et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR[J]. Proc Natl Acad Sci USA,2009,106(10):3794-3799.
[26] WANG Y,YI J,CHEN X,et al. The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-βand IL-10[J]. Oncology Letters,2016,11(2):1527-1530.
[27] RAHMAN MA,BARGER JF,LOVAT F,et al. Lung cancer exosomes as drivers of epithelial mesenchymal transition[J]. Oncotarget,2016,7(34):54852-54866.
[28] TAYLOR DD,GERCEL-TAYLOR C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer[J]. Gynecol Oncol,2008,110(1):13-21.
[29] SUN T,KALIONIS B,LV G,et al. Role of Exosomal Noncoding RNAs in Lung Carcinogenesis[J]. Biomed Res Int,2015,2015:125807.